Evofem Biosciences, Inc.
For the period ended Nov 26, 2025. Filed Nov 26, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 26, 2025 · Filed Nov 26, 2025
Use the contents to explore the available documents and sections.
Contents
Proposal
Proposal 1
Election of the following nominees as Class I or Class II directors of the Company, to serve three-year terms until the 2028 Annual Meeting of Stockholders and until their successor is duly elected and qualified.
| Votes For | Votes Against | Votes With held | Broker Non-Vote | |
|---|---|---|---|---|
| Kim Kamdar, Ph.D. (Class I Director) | 167,426,206 | - | 1,831,252 | 43,969,625 |
| Colin Rutherford (Class I Director) | 167,375,794 | - | 1,881,664 | 43,969,625 |
| Lisa Rarick (Class I Director) | 167,416,947 | - | 1,840,511 | 43,969,625 |
| Tony O’Brien (Class II Director) | 167,357,011 | - | 1,900,447 | 43,969,625 |
Each of the four nominees were elected to the Board by the Company’s stockholders, each to hold office until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected or until his or her resignation or removal.
Proposal 2
Approval, on a non-binding advisory basis, of the compensation of our named executive officers (“Say-on-Pay”).
| Votes For | Votes Against | Abstentions | Broker Non-Vote |
|---|---|---|---|
| 155,458,669 | 13,342,767 | 456,023 | 43,969,624 |
This proposal was approved by the Company’s stockholders voting together as a class.
Proposal 3
Approval of the Evofem Biosciences, Inc. 2025 Equity Incentive Plan.
| Votes For | Votes Against | Abstentions | Broker Non-Vote |
|---|---|---|---|
| 161,228,017 | 7,369,458 | 659,984 | 43,969,624 |
This Evofem Biosciences, Inc. 2025 Equity Incentive Plan was approved by the Company’s stockholders voting together as a class.
Proposal 4
Approval of an amendment to the Company’s Certificate of Incorporation to authorize a reverse stock split of the outstanding Common Stock by a ratio of not less than 1-for-500 and no more than 1-for-1,500, with the exact range to be set a whole number within such range by the Board, in its sole discretion, at any time prior to November 26, 2026.
| Votes For | Votes Against | Abstentions | Broker Non-Vote | |
|---|---|---|---|---|
| Common, Series E-1 and Series G-1 Combined | 171,747,197 | 41,462,277 | 17,606 | 3 |
| Series E-1 | 37,967,769 | - | - | - |
| Series G-1 | 103,578,947 | - | - | - |
Approval of this proposal required (i) the affirmative vote of a majority of the combined voting power of the outstanding shares of Common Stock, Series E-1, and Series G-1, voting together as a single class, and (ii) the affirmative vote of a majority of the outstanding shares of each of Series E-1 and Series G-1 Preferred Stock, voting separately as classes.
Proposal 4 was approved by a majority of the combined voting power of the Common Stock, Series E-1, and Series G-1 voting together as a single class and by a majority of each of Series E-1 and Series G-1 voting separately as classes.
Proposal 5
Ratification of the appointment of BPM LLP as the Company’s Independent Registered Public Accounting firm for the year ending December 31, 2025.
| Votes For | Votes Against | Abstentions | Broker Non-Vote |
|---|---|---|---|
| 210,500,099 | 2,289,164 | 437,817 | 3 |
The appointment was ratified by the Company’s stockholders voting together as a class.
Proposal 6
Because a quorum was present and sufficient votes were received to approve all other proposals, no vote on Proposal 6 was required or taken.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.